Brief: Karyopharm Reports Fourth Quarter And Full Year 2025 Financial Results And Highlights Recent Company Progress
12/02/2026 13:01
Feb 12 (Reuters) - Karyopharm Therapeutics Inc KPTI.O: KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS Source text: ID:nPnFXdqga Further company coverage: KPTI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview